In development [GID-TA10440] Expected publication date: TBC
4 results for anticoagulation
We are listening to your views on this technology appraisal guidance. Comments close 02 October 2020.
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing adverse outcomes after acute management of acute coronary syndrome (ACS)
In development [GID-TA10626] Expected publication date: 21 July 2021